Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease

Genoss

Status: Active, not recruiting

Conditions: Coronary Arterial Disease (CAD)

Study type: Observational

Funder types: Industry

Identifiers

NCT06841510

CIP-DS0501-09

Details and patient eligibility

About

Efficacy and Safety of GENOSS SES in patients with coronary artery disease

Full description

GENOSS SES

Enrollment: 1,118 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients of 19 and over
2. Patients with coronary artery disease treated with GENOSS SES
3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants

Exclusion criteria

1. Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents
2. Patients who are pregnant or planning to become pregnant
3. Patients with a planned surgery to discontinue antiplatelet agents within 12 months
4. Patients with a life expectancy of less than 1 year
5. Patient with cardiogenic shock at the time of hospitalization and had a low chance of survival based on medical judgment.
6. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration
7. Patients participating in randomized controlled trials using other medical devices

Trial design

1,118 participants in 1 patient group

GENOSS Sirolimus Eluting Coronary Stent System

Description:

patients with coronary artery disease treated with GENOSS SES